Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Zhijie WangLin WuBaolan LiYing ChengXiaoling LiXicheng WangLiang HanXiaohong WuYun FanYan YuDongqing LvJianhua ShiJianjin HuangShaozhang ZhouBaohui HanGuogui SunQisen GuoYouxin JiXiaoli ZhuSheng HuWei ZhangQi-Ming WangYuming JiaZiping WangYong SongJingxun WuMeiqi ShiXingya LiZhigang HanYunpeng LiuZhuang YuAn-Wen LiuXiuwen WangCaicun ZhouDiansheng ZhongLi-Yun MiaoZhihong ZhangHui ZhaoJun YangDong WangYingyi WangQiang LiXiaodong ZhangMei JiZhenzhou YangJiuwei CuiBeili GaoBuhai WangHu LiuLei NieMei HeShi JinWei GuYongqian ShuTong ZhouJian FengXinmei YangCheng HuangBo ZhuYu YaoXiongwen TangJianjun YuEllen MaherHui FengSheng YaoPatricia KeeganJie WangPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Toripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC while having a manageable safety profile. Subgroup analysis showed the OS benefit was mainly driven by the nonsquamous subpopulation.